Alexion Pharmaceuticals — Merger or Acquisition (December 2020)
26 slides from Alexion Pharmaceuticals's merger presentation, Dec 14, 2020
Slide 1: Forward-looking statements
Forward-looking statements This document may include statements that are or may be deemed to be forward-looking statements. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "envisages", "plans", "projects", "an
Slide 2: Disclaimer: Important additional information
Disclaimer Important additional information Neither this presentation nor any copy of it may be taken or transmitted directly or indirectly into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction. Any failure to comply with t
Slide 3: AstraZeneca's transformation has been pipeline-led
AstraZeneca’s transformation has been pipeline-led Broad presence Strong pipeline Improving financials Balanced specialty and primary-care franchises1 17 Phase III medicines and Nine blockbuster medicines significant lifecycle projects Returned to sustainable Leading emerging markets Advancing early
Slide 4: AstraZeneca has been expanding its Immunology effort
AstraZeneca has been expanding its Immunology effort a and epithelial injury across 1 2 Medium-term Long-term Near-term 3 Anifrolumab in SLE Cement our position as a leader in Immunology Deliver world-class anifrolumab launch us R&D on area of high unmet need Initiate LCM for anifrolumab, cision med
Slide 5: Alexion is aligned with our strategy
Alexion is aligned with our strategy Our external growth strategy is anchored in clear principles Aligns with AstraZeneca’s strategy -Deliver therapy area leadership -Accelerate innovative science AstraZeneca adding value through therapy-area leadership, scientific complementarity, and/or geographic
Slide 6: Alexion is a global leader in immune-mediated rare diseases
Industry-leading growth Strong financials diseases1 Alexion is a global leader in immune-mediated rare e e diseases progress made over the last several years 7,000 20% 18% AG10 (e.g. growth, LCM, pipeline expansion) CAGR CAGR 6,000 CAEL-101 • Global leader in the complement system, a critical part o
Slide 7: Alexion: a pioneer innovator in C5 complement inhibition
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: a pioneer innovator in C5 complement inhibition Bringing life-saving medicines to more patients 3rd Gen (Phase 1) Expansion to larger rare / specialty >100K potential addressable patients (so far) Ph1
Slide 8: Alexion: a pioneer innovator in C5 complement inhibition
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: a pioneer innovator in C5 complement inhibition Bringing life-saving medicines to more patients 3rd Gen (Phase 1) Expansion to larger rare / specialty >100K potential addressable patients (so far) Ph1
Slide 9: Alexion: accelerating AZ's strategic and financial development
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: accelerating AZ’s strategic and financial development Compelling scientific complementarity and synergy › › › Increased immunology presence: complement system research platform, currently applied in ra
Slide 10: Alexion: accelerating AZ's strategic and financial development
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Alexion: accelerating AZ’s strategic and financial development Compelling scientific complementarity and synergy › › › Increased immunology presence: complement system research platform, currently applied in ra
Slide 11: Combined R&D capabilities cover both adaptive and innate immunity
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Combined R&D capabilities cover both adaptive & innate immunity Improved ability to identify attractive new targets Adaptive Immunity Cell Mediated Innate Immunity Humoral LectinClassical Alternative Factor B T
Slide 12: Complement pathway opportunities across therapy areas
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Haematology Cold agglutinin diseasePNH TTP wAIHA Nephrology aHUS C3G IgA nephropathy Haemodialysis Multiple Neurology GBS gMG NMOSD Dermatomyositis Mood disorders Dementia Neurotrauma Respiratory Asthma Acute r
Slide 13: Convergence of two patient-centric care deliveries
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Convergence of two patient-centric care deliveries Scientific platforms supporting complementary development and commercial channels Common Diseases Less Common Diseases Rare Diseases Prescribers GPs / PCPs Spe
Slide 14: Strong C5 franchise and innovative assets
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Strong C5 franchise, and a number of innovative assets Market-leading and highly durable C5 franchise (Soliris / Ultomiris) › › › Proven impressive product conversion expertise; next generation innovative C5 fo
Slide 15: Complementary cultures with shared focus on patients
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Complementary cultures with shared focus on patients • Two companies with shared mission and purpose – to create value for patients through delivery of innovative medicines › Opportunity for shared learnings an
Slide 16: Biopharma innovator with strong profitability
Scientific leadership Shared purpose and values Industry-leading growth Strong financials biopharma innovator with strong profitability, ding science and growth Superior Financials ster medicines1, growing ogy, to 12 by 20232 Ms CVRM and Respiratory & Immunology, with strong est growing global rmace
Slide 17: Biopharma innovator with strong profitability
Scientific leadership Shared purpose and values Industry-leading growth Strong financials biopharma innovator with strong profitability, ding science and growth Superior Financials ster medicines1, growing ogy, to 12 by 20232 Ms CVRM and Respiratory & Immunology, with strong est growing global rmace
Slide 18: Portfolio to drive sustainable growth
Scientific leadership Shared purpose and values Industry-leading growth Strong financials ortfolio to drive sustai M5, R&I - Organ protection and immune-mediated diseases blood cancers Farxiga, Brilinta, Andexxa, pipeline • • Strensiq, Kanuma • Tagrisso, Imfinzi, Lynparza, Calquence, • Kidney Farxig
Slide 19: The combination cements AstraZeneca's growth leadership
Scientific leadership Shared purpose and values Industry-leading growth Strong financials The combination cements AstraZeneca’s growth leadership AZ double-digit revenue growth AstraZeneca vs. sector peers revenue CAGR (2021E-2024E) New Company Company Company Company Company Company Company Company
Slide 20: The combination cements AstraZeneca's growth leadership
Scientific leadership Shared purpose and values Industry-leading growth Strong financials The combination cements AstraZeneca’s growth leadership AZ double-digit revenue growth AstraZeneca vs. sector peers revenue CAGR (2021E-2024E) New Company Company Company Company Company Company Company Company
Slide 21: Rare diseases is a strong growth driver
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Rare diseases is a strong growth driver Accelerating growth and innovation in an area of high unmet needs Rare diseases are a significant burden to global public health Worldwide rare disease market sales forec
Slide 22: Strengthening US presence and leveraging global footprint
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Strengthening US presence and leveraging global footprint AstraZeneca Combined company Alexion Other EM EM 13% RoW US 33% Other EM 9% Japan 21% 9% China 12% US 59% US 19% RoW 19% 10% 38% China 17% Europe Japan
Slide 23: Integration provides enhanced US and global presence
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Integration provides enhanced US and global presence AstraZeneca Global with large presence in emerging markets R&D in Cambridge, Gothenburg and Gaithersburg () with satellite R&D in Boston Provides greater pla
Slide 24: Attractive financial profile with strong revenue growth
p Shared purpose and values Industry-leading growth Strong financials ctive financial profile with strong revenue growth months1) ma financials (last twelve 10% 32% h Core operating profit margin n $28bn company financial statements over the last four quarters. EBITDA based on reported (AstraZeneca)
Slide 25: Capital-allocation priorities
Scientific leadership Shared purpose and values Industry-leading growth Strong financials Capital-allocation Alexion supports value priorities creation accretive, value-enhancing progressive 22 Maintaining a strong, investment-grade credit rating Supporting the dividend policy Investment in the busi
Slide 26: Growth sustainability underpinned by longevity beyond 2030
Growth sustainability underpinned by longevity beyond 2030 Uttomiris Tezepelumab DS-8201 AKT Inhibitor ‘monalizumab Lokelma Tagrisso Calquence Imtfin2i Breztri Kanuma Pr027 Fasenra Strensiq Lynparza Soliris 2025 2030 2035 BD oncology B® crew BD Respiratory & immunology BD Pore disease S
Alexion Pharmaceuticals — Merger or Acquisition (December 2020) on 6ix